Unknown

Dataset Information

0

Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors.


ABSTRACT: P-Glycoprotein (P-gp, ABCB1) plays a significant role in determining the ADMET properties of drugs and drug candidates. Substrates of P-gp are not only subject to multidrug resistance (MDR) in tumor therapy, they are also associated with poor pharmacokinetic profiles. In contrast, inhibitors of P-gp have been advocated as modulators of MDR. However, due to the polyspecificity of P-gp, knowledge on the molecular basis of ligand-transporter interaction is still poor, which renders the prediction of whether a compound is a P-gp substrate/non-substrate or an inhibitor/non-inhibitor quite challenging. In the present investigation, we used a set of fingerprints representing the presence/absence of various functional groups for machine learning based classification of a set of 484 substrates/non-substrates and a set of 1935 inhibitors/non-inhibitors. Best models were obtained using a combination of a wrapper subset evaluator (WSE) with random forest (RF), kappa nearest neighbor (kNN) and support vector machine (SVM), showing accuracies >70%. Best P-gp substrate models were further validated with three sets of external P-gp substrate sources, which include Drug Bank (n = 134), TP Search (n = 90) and a set compiled from literature (n = 76). Association rule analysis explores the various structural feature requirements for P-gp substrates and inhibitors.

SUBMITTER: Poongavanam V 

PROVIDER: S-EPMC3445814 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors.

Poongavanam Vasanthanathan V   Haider Norbert N   Ecker Gerhard F GF  

Bioorganic & medicinal chemistry 20120329 18


P-Glycoprotein (P-gp, ABCB1) plays a significant role in determining the ADMET properties of drugs and drug candidates. Substrates of P-gp are not only subject to multidrug resistance (MDR) in tumor therapy, they are also associated with poor pharmacokinetic profiles. In contrast, inhibitors of P-gp have been advocated as modulators of MDR. However, due to the polyspecificity of P-gp, knowledge on the molecular basis of ligand-transporter interaction is still poor, which renders the prediction o  ...[more]

Similar Datasets

| S-EPMC3904775 | biostudies-literature
| S-EPMC8479898 | biostudies-literature
| S-EPMC6571636 | biostudies-literature
| S-EPMC3969253 | biostudies-literature
| S-EPMC6890515 | biostudies-literature
| S-EPMC6073570 | biostudies-literature
| S-EPMC2791418 | biostudies-literature
| S-EPMC6044698 | biostudies-literature
| S-EPMC9316655 | biostudies-literature
| S-EPMC5367765 | biostudies-literature